Paclitaxel is the most commonly used chemotherapeutic agent in breast cancer treatment. In addition to its well-known cytotoxic effects, recent studies have shown that paclitaxel has tumor-supportive activities. Importantly, paclitaxel levels are not maintained at the effective concentration through one treatment cycle; rather, the concentration decreases during the cycle as a result of drug metabolism. Therefore, a comprehensive understanding of paclitaxel's effects requires insight into the dose-specific activities of paclitaxel and their influence on cancer cells and the host microenvironment. Here we report that a low dose of paclitaxel enhances metastasis of breast cancer cells to the liver in mouse models. We used microarray analysis to investigate gene expression patterns in invasive breast cancer cells treated with low or clinically relevant high doses of paclitaxel. We also investigated the effects of low doses of paclitaxel on cell migration, invasion and metastasis in vitro and in vivo. The results showed that low doses of paclitaxel promoted inflammation and initiated the epithelial-mesenchymal transition, which enhanced tumor cell migration and invasion in vitro. These effects could be reversed by inhibiting NF-jB. Furthermore, low doses of paclitaxel promoted liver metastasis in mouse xenografts, which correlated with changes in estrogen metabolism in the host liver. Collectively, these findings reveal the paradoxical and dosedependent effects of paclitaxel on breast cancer cell activity, and suggest that increased consideration be given to potential adverse effects associated with low concentrations of paclitaxel during treatment.
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Introduction
With one million new cases worldwide each year, breast cancer is the most common malignancy and ranks second in cancer mortality for women [1] . Strikingly, the main cause of death for breast cancer is not Abbreviations 4-OHE2, 4-hydroxyestradiol; CCL20, chemokine (C-C motif) ligand 20; COMT, catechol-O-methyltransferase; CXCL1, chemokine (C-X-C motif) ligand 1; CYP, cytochrome P450; EMT, epithelial-mesenchymal transition; ICAM1, intercellular adhesion molecule 1; IKK, IjB kinase; IL, interleukin; NF-jB, nuclear factor-jB; PTX, paclitaxel; TNF, tumor necrosis factor; VCAM1, vascular cell adhesion molecule 1.
the primary tumor, but its metastasis [2, 3] . Based on the century-old 'soil and seeds' theory, the interaction between metastatic cells and the microenvironment in host organs is critical for the formation of lethal metastases with organ specificity [4] [5] [6] [7] [8] . Clinically, breast cancer is preferable to dissemination to lungs, liver, brain and bones [9] . Among these four organs, liver is the third most susceptible site, and breast cancer with liver metastasis is statistically proven to be the predictive factor for drug resistance and poor prognosis [10] [11] [12] .
Until now, despite the intense debate regarding its efficacy and safety, chemotherapy remains the most favorable option after surgical removal to eradicate breast tumor cells. Paclitaxel (PTX) is the first-line agent for breast cancer, especially for metastatic or HER2-negative breast cancer [13, 14] . It possesses multiple anti-tumor activities [15] . The classical pharmacological activity of PTX is that it disrupts microtubule dynamics by promoting tubulin polymerization and stability as well as inducing apoptosis and cell cycle arrest in tumor cells [16, 17] . Additionally, a variety of tumor-inhibitory effects of PTX through other mechanisms have recently been revealed [18] [19] [20] . For example, it has been found that PTX, with prolonged exposure time and metronomic schedules, may have anti-angiogenic properties [21] . Moreover, previous studies have clearly revealed that the efficacy of PTX in malignant cells is highly dose-dependent. It exerts diverse effects via specific mechanisms at different doses [22] [23] [24] [25] .
Apart from its tumor-suppressive effects, PTX in clinical concentration elicits a transient 'cytokine storm' in breast cancer patients [26, 27] . The proinflammatory effect of PTX is dependent on Toll-like receptors (TLRs) signaling and has been proven to be the primary effect resulting in cancer treatment failure, tumor resistance or even induction of the lymph node and pulmonary metastasis of breast cancer [28, 29] . However, the influence of PTX on other organ-targeted metastases of breast cancer and its direct regulation in the host organ, most importantly in the liver microenvironment, remains missing.
Pharmacokinetically, PTX was selectively enriched and metabolized in liver [30] . However, its metabolism and distribution features are highly individual. In addition, accompanying PTX metabolism and degradation in vivo, the effective PTX concentration dynamically decreases. Therefore, it is inevitable and non-negligible that the PTX concentration will be far lower than the clinical dose in tumor tissues, especially in the later phase of one medication cycle. Clinically, restricted by the severe cytotoxic effects, the 'low-dose metronomic' chemotherapeutic pattern is preferable for most Asian patients [31] and the medication cycle of PTX usually contains long dosing intervals. These lead to the increased opportunity for exposure or prolonged exposure time to low-dose PTX in cancer patients. Taking the dose-dependent feature of PTX efficacies into account, a detailed analysis of PTX efficacy at low dose and its relevance to tumor progression is necessary and will be beneficial for reasonable PTX application; however, such studies are still lacking.
Collectively, our study was designed to reveal how low-dose PTX regulates tumor disease progression and to identify the influence of low PTX on host organ microenvironment.
To complete our study, we compared the effects of PTX with the clinical dose (equivalent to 20 mgÁkg À1 in mouse) or lower than the clinical achievable dose in breast tumor-bearing mouse models. Surprisingly, we found that low and high doses of PTX showed completely different efficacies. Low-dose PTX induced more liver metastasis, which greatly attracted our attention. Further study for the first time revealed that low-dose PTX, with little tumoricidal effect, functioned as a potent inducer for breast cancer progression in a nuclear factor-jB (NF-jB) -dependent manner. We also observed the expression changes of drug metabolic enzymes in host hepatocytes, which might result in the oncological rebuilding of the estrogen metabolic balance and the promoting of metastasis in the liver microenvironment. Our study provided experimental indications of how to avoid the sideeffects and optimize the toxicity-efficacy ratio of PTX and will be beneficial for the reasonable application of PTX during cancer treatment.
Results

High and low doses of PTX show different efficacies on breast cancer cells
According to chemotherapeutic strategy, the clinically used dose of PTX is 90-200 mgÁm À2 , which is equivalent to 20-50 mgÁkg À1 in mouse. To compare the effects of different doses of PTX on tumor progression in vivo, MDA-231 tumor-bearing mice were treated with low-dose (1 mgÁkg À1 ) and high-dose (20 mgÁkg À1 ) PTX. In contrast to the efficient restriction of primary tumor in the high-PTX group (Fig. 1A,B) , liver metastases were obviously induced in the low-PTX group with little influence on primary tumor growth (Fig. 1A-D) . Morphologically, a large number of 1-3 mm diameter, pale-colored, dotted or plaque-like metastases can be directly observed in liver samples collected from the low-dose PTX group. Histologically, hemotoxylin and eosin staining also showed that the light-colored spotted metastases were dramatically increased in livers from the low-dose PTX-treated mice. In contrast, the metastasis was substantially reduced in the high-dose PTX group compared with the negative control (Fig. 1E) . Of note, in the same animal model, low-dose PTX did not affect cancer cells metastasizing to lungs, one of the most susceptible organs for breast cancer metastasis (Fig. 1F) .
Moreover, to dynamically and specifically characterize the results mentioned above, the high-invasive mouse breast cancer cell 4T1, which can spontaneously metastasize to lungs in vivo, was selected for a tumor model. It was further constructed to stably express luciferase (4T1-Luc), and a small animal imaging system was used to trace and quantify the influence of PTX on the progression of breast cancer in vivo. Consistent with the above results, images and quantification data (Fig. 2) clearly showed that high-dose PTX obviously inhibited the primary tumor growth, whereas such effects cannot be detected in the lowdose PTX group. The tumor weight and the total photon values showed no significant difference between negative control and the low-PTX-treated group, and The results showed that low-dose PTX induced liver metastasis in vivo, whereas it had no influence on metastasis to the lungs, which are also a common target for breast cancer metastasis. Scale bar: 20 lm. All the bar graphs show means AE standard deviation from three independent repeats. One-way analysis of variance (ANOVA) was used for all the quantifications: **P < 0.01.
were about more than 2 times higher than those in the high-PTX group ( Fig. 2A-C) . In contrast, the metastatic behavior was greatly influenced by low-dose PTX. In the later phase of tumor progression, the lung metastases can be clearly detected and their intensities kept at a similar level in the negative control and the low-PTX group. However, liver preferential metastasis can be obviously and specifically detected in response to low PTX. As expected, high PTX efficiently suppressed the metastatic colonization of breast cancer in all of the four susceptible organs (Fig. 2D,E) . This result provided further evidence for the promotion effect of low PTX on the liver metastases of breast cancer.
Low-dose PTX induces the expression of genes mediating cancer-related inflammation in MDA-231 cells
To further reveal the underlying effects of low-dose PTX at the molecular level, gene microarray analysis was performed. In genome-wide screening and cluster analysis, the low-dose PTX responsive genes exhibited a typical proinflammatory signature ( Fig. S1 and Fig. 3A , Table 1 ).
Subsequently, 100 ngÁmL À1 clinical-dose PTX (for clinical use, the equivalent PTX concentration in vitro ranges from 85 to 2500 ngÁmL À1 [25, 32] ) and ultralow-dose PTX (less than 30 ngÁmL À1 ) were used and the prediction from microarray analysis was identified in vitro. Firstly, we found that, consistent with the clinical-dose PTX, low-dose PTX also possessed potent activity to enhance the expression of inflammatory molecules in a wide-spectrum of tumor cells. These cell lines were originated from the malignancies that were the typical PTX-responsive tumors in clinical treatment, including breast cancer, lung cancer and ovarian cancer (Fig. 3B) . Furthermore, using MDA-231 as the model, detailed analysis identified that, with little alteration in cell survival ( Fig. 3C) , chemokines, cytokines and inflammatory adhesion molecules were all elevated at both the mRNA and the protein levels in low-dose PTX-treated cells. For example, low PTX induced more than 200-folded and 2000-folded transcriptional upregulation for interleukin (IL) 8 and chemokine (C-C motif) ligand 20 (CCL20), respectively. Accordingly, the secretion levels of IL8 and IL6 were about five times and three times higher, respectively, than negative control (Figs 3D-F and 4A-F).
The above molecular changes were also proved in vivo. In low-dose PTX-exposed tumor-bearing mice, the above-mentioned inflammatory cytokines or chemokines were all elevated systematically (Fig. 4G,H) . In addition, low-dose PTX induced the expression of the inflammation adhesion molecules, including intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), in primary tumor samples (Fig. 4I ).
Low-dose PTX directly induces the epithelialmesenchymal transition and functionally enhances breast tumor motility and invasion
In addition to the above findings, the detailed molecular analysis further indicated that, different from clinical-dose PTX, low-dose PTX not only resulted in similar proinflammatory and angiogenic responses in the host microenvironment as reported by Lisa VolkDraper and colleagues [29] , but also directly had a promalignant effect on tumor cells themselves. Under low-dose PTX treatment, the molecular expression change revealed a clear epithelial-mesenchymal transition (EMT) profile. E-cadherin, a well-known epithelial marker and potent metastatic inhibitor, was reduced. Conversely, the mesenchymal marker vimentin, the EMT mediator integrin b3 and the initiator Twist were all significantly upregulated in response to low PTX treatment (Fig. 5A ). These changes were further identified in primary tumor samples obtained from an animal model (Fig. 5B ). This suggested that the effects of PTX are highly dependent on its dose. At high concentration, due to the potent tumoricidal effect, PTX functions as a suppressor of tumor growth. In contrast, when dose decreases, the tumor toxic effect of PTX is largely weakened and only the promalignant effects can be predominantly detected. Fig. 2 . Low-dose PTX has little inhibitory effect and enhances the liver metastasis of breast cancer in vivo. To observe the disease progression in a broader range, 4T1-Luc cells were transplanted into Balb/C mice (10 mice per group) and designed to grow over a longer time compared with the model in Fig. 1 . After regular PTX administration, the primary tumor images were collected (A) and their weights and total photon values were quantified (B, C). The result revealed that the tumor-inhibitory effect was largely weakened by the decrease of PTX dose. Scale bar: 1.8 cm. (D) Images of metastatic lesions in liver and lungs. Representative images are shown (three mice per group). Scale bar: 7 mm. (E) Total photon analysis for the target organs of breast cancer metastasis (liver, lungs, brain and bone). The result further identified the liver metastasis promoting effect of low-dose PTX. All the bar graphs show means AE standard deviation from three independent repeats. One-way ANOVA was used for all the quantifications: *P < 0.05, **P < 0.01, ***P < 0.001. Results showed that, compared with PTX-non-treated cells, the expressions of chemokines (IL8, CCL20, CXCL1), inflammatory cytokines (IL1B, TNF, IL6) and adhesion molecules (VCAM1 and ICAM1) were all obviously upregulated by low-dose PTX. All the quantitative data in (C-F) are means AE standard deviation from three independent repeats. One-way ANOVA was used for all the quantifications: *P < 0.05, **P < 0.01, ***P < 0.001. CCL20, chemokine (C-C motif) ligand 20; CXCL1, chemokine (C-X-C motif) ligand 1; ICAM1, intercellular adhesion molecule 1; IL6, interleukin 6; IL8, interleukin 8; TNF, tumor necrosis factor; VCAM1, vascular cell adhesion molecule 1.
To further investigate whether the molecular changes led to functional alterations of breast tumor cells, the Transwell cell migration assay was performed. By treating MDA-231 cells with 0.5 and 1.5 ngÁmL À1 PTX, the transmembrane rate was significantly increased in the low-PTX groups (Fig. 5C ).
Moreover, in a cell detachment assay, an increased number of adherent cells were observed in a dosedependent manner. In the negative control group, the trypsinized cells had a rounded morphology and were dissociated from the matrix, whereas cells treated with 5-15 ngÁmL À1 PTX maintained a spindle cell shape. These results revealed that the cells were more resistant to trypsinization after PTX treatment, further demonstrating that PTX treatment promoted cell adhesion (Fig. 5D) . Accordingly, actin polymerization was also obviously enhanced in low-PTXtreated MDA-231 cells, which suggested a promigration effect of low PTX in breast cancer cells (Fig. 5E ).
To further mimic the process of tumor cell invasion and infiltration into surrounding tissue in vitro, the Matrigel cell invasion assay was performed. Figure 5F shows that the transmembrane rate was about three times higher than that in negative control cells. Notably, breast cancer cells respond specifically to low-dose PTX in the promotion of tumor invasiveness. High-dose PTX (100 ngÁmL À1 ) failed to induce the same phenotypic changes as low-dose PTX. Its transmembrane cells were about 10 times lower than the low-dose PTX group. These results phenotypically supported the molecular alteration induced by low-dose PTX.
Activation of NF-jB is required for the oncological behaviors induced by low-dose PTX Based on the central roles of NF-jB in the regulation of tumor-associated inflammation and cancer progression, we next examined the connection between lowdose PTX and NF-jB. In a dual-luciferase reporter gene assay, we found about 8-fold higher luminescence intensity in the low-PTX group compared with the control group, initially revealing that NF-jB was activated by low-dose PTX (Fig. 6A) . Western blot analysis further confirmed the NF-jB activating effects of low-dose PTX on breast tumor cells from both in vivo and in vitro models. The phosphorylation levels of IjB kinase (IKK) and p65 were elevated, whereas the essential NF-jB inhibitor, IjB, was significantly downregulated in response to low PTX (Fig. 6B,C) .
Additionally, by treatment with the NF-jB inhibitor BAY117082 (BAY), the inflammation-stimulating activity of low-dose PTX was largely inhibited (Fig. 6D) . For instance, the transcriptional level of IL8 in PTX and BAY combined-treated cells was eight times lower than that in cells treated with PTX alone. Furthermore, consistent with the molecular changes, in a Transwell assay, the number of transmembrane cells in the combined treated group was 134, which was 4.3 times lower than that in the PTX-non-treated group (Fig. 6E) . These results functionally suggest that NFjB is responsible for the upregulated inflammation and the enhanced tumor motility induced by low-dose PTX. Results revealed that the key factors mediating inflammation were systematically induced in low-PTX-exposed mice. (I) Western blot analysis of the adhesion molecules in primary tumors from low-PTX-treated tumor-bearing mice. Two mice primary tumor samples from each group were selected to detect the expression of adhesion molecules. Representative results from two mice in the same group (Mouse 1 and 2) are shown and the gray value of each sample compared with its internal control is statistically quantified below. These data further support the proinflammatory effects of lowdose PTX in vivo. The bar graphs show means AE standard deviation from three independent repeats. One-way ANOVA was used for all the quantifications: *P < 0.05, **P < 0.01.
Low-dose PTX induces changes in estrogen metabolism in liver that facilitate the formation of breast cancer metastases
Next, we attended to the mechanism of the liver metastatic preference induced by low-dose PTX. In this study, we noticed that PTX is selectively enriched and metabolized in liver [30, 33] . Led by this, we found that two PTX-related metabolic enzymes [34, 35] , cytochrome P450 1B1 (CYP1B1) and Cytochrome P450 3A4 (CYP3A4), were significantly induced in low-dose PTX-treated HepG2 cells (Fig. 7A,B) . The transcriptional intensity of CYP1B1 was four times higher in low-PTX-treated cells. Interestingly, recent studies clearly showed that CYP1B1 was the risk factor involved in chemotherapy resistance in breast cancer patients [35] and functionally participated in the oncological metabolism of the carcinogen 4-hydroxyestradiol (4-OHE2), which enhances malignancy of multiple cancer cells in both an estrogen-dependent and -independent manner [36] [37] [38] . Led by this, the above mRNA alteration was further identified in All the quantitative data are collected from three independent repeats and represented by means AE standard deviation. One-way ANOVA was used for all the quantifications: *P < 0.05, **P < 0.01.
tumor-free mice injected with 1 mgÁkg À1 PTX for three courses of treatment intraperitoneally. The result showed that the CYP1B1 expression level was course-dependently upregulated (Fig. 7C) . To the contrary, catechol-O-methyltransferase (COMT), the enzyme responsible for the detoxification of 4-OHE2 into methoxy derivatives [39] , was obviously reduced in PTX-treated liver samples (Fig. 7D,E) . Collectively, our results provided dual support, by selective enrichment in the liver, for low PTX resulting in the dysregulated expression of estrogen metabolic enzymes, which might contribute to the oncological shift of estrogen metabolism.
Discussion
PTX and its analogous compounds are the first line agents widely used in clinical cancer chemotherapy. However, potential risks and reasonable treatment strategies of PTX continue to be widely investigated [28] . Based on our study, we firstly observed that, specifically responding to low-dose PTX, metastases in liver colonized with much higher intensity than that in the negative control or the high-PTX group. We next revealed that the low and clinical doses of PTX have similar effects on the regulation of cancer-related The results indicated low PTX induced the procarcinogenic gene expression profile for estrogen metabolism. The histograms show means AE standard deviation collected from three independent experiments. One-way ANOVA was used for all the quantifications: *P < 0.05, **P < 0.01.
inflammation. In contrast, with little tumor-killing effect, the low-dose PTX-responsive genes have been well proven to extensively participate in tumor progression [40] [41] [42] [43] . For instance, our study revealed that low-dose PTX induced more than 2000-fold upregulation of CCL20, which has been identified as the potent promalignant factor in breast cancer [44, 45] . More importantly, in clinical survey, this gene expression pattern shares similarities with that of patients with inflammatory breast cancers. Many of the genes (COX2 or CXCL1) are further confirmed to be the core pathogenic factors for inflammatory breast cancers, which is highly consistent with our results [46] . Noteworthy, different from high-dose PTX, lowdose PTX not only molecularly induced the inflammatory response, but also functionally supported the tumor cell motility and invasive potential through the induction of EMT, which cannot be observed in the clinical-dose group. The transmembrane rate in the low-PTX-treated group was 2.7 times higher than that in the negative control. Based on such evidence, we have reason to note that, in addition to the similar efficacies in inflammatory promotion, low-dose PTX can directly potentiate tumor malignancy.
From the above results, we postulated that PTX has conflicting but highly correlated activities on malignancies: immune regulation and tumor cytotoxicity. The efficacy output for PTX is determined by its functional balance and our study clearly revealed that this balance is highly regulated by its dose. At clinically high dose, it exerts predominantly tumor-killing efficacy and efficiently blocks the progression of malignancies. Conversely, at the low concentration, PTX fails to function as the tumor suppressor but retains the potential to activate the NF-jB pathway. This leads to the rebalance of PTX efficacies, primarily inducing the repolarization of tumor cells and the reconstruction of the host microenvironment, which are both considered to be the main mechanism forcing tumor metastasis.
In addition to strengthened metastatic potential, we further obtained some indicative insights into the regulation of the hepatic microenvironment by PTX. It is well proven that PTX is selectively enriched in liver, and hepatic metabolism is the main elimination pathway for PTX [33] . In our studies, we found that low-dose PTX induced expression changes of drug metabolic enzymes (CYP1B1 and CYP3A4) in liver from tumor-free mice. In addition to their PTX metabolic activity [34, 47] , these enzymes are responsible for the hydroxylation of estrogens and activation of potential carcinogens in an estrogen receptorindependent mechanism [36, 37] . CYP1B1 is the core Fig. 8 . Brief summary of the prometastatic effect of low-dose PTX in liver. The re-established balance for low-dose PTX stimulates cancerrelated inflammation (CRI) and oncologically promotes the malignancy. In addition, by being selectively enriched and detoxified in liver, lowdose PTX might induce a functional shift in estrogen metabolism and facilitate the formation of metastases in liver. mediator during estrogen receptor-independent carcinogenesis via activation of potential pathogenic factors [48] . Moreover, through catalysis of estrogen to 4-hydroxyestrogens, CYP1B1 is responsible for the activation of the invasive potential in human endometrial carcinomas [49] . Additionally, low-dose PTX also significantly and negatively influenced the expression of COMT, the major detoxifying enzyme for 4-hydroxyestrogens [39] . Collectively, we hypothesized that low-dose PTX can induce the dysregulated expression of estrogen metabolic enzymes and might provide a tumor-promoting microenvironment that facilitates the formation of metastases in liver.
In conclusion, in both immune-deficient and intact animal models, our findings proved that low-dose PTX enhanced liver-preferential metastasis and this phenomenon was determined by the synergistic integration of promalignant effects on breast tumor cells and the carcinogenic metabolism of estrogen in the liver microenvironment (Fig. 8) . In light of the existing evidence, we can naturally extrapolate that lowlevel PTX, resulting from metabolic processes, drug distribution differences or individual variation, not only invalidates the clinical treatment, but also represents a risk factor that will lead to the promotion of malignancy and treatment failure. Notably, in current strategies for clinical therapy, a comprehensive and combined treatment is widely used in breast cancer. By the integration and complementation of different drug efficacies, the lowering of PTX dose with the aim of reducing toxic side-effects is adopted by most clinicians and believed to be beneficial for therapy optimization. In contrast with this belief, the results of our study alert us that such a strategy may have unexpected side-effects and should be carefully considered.
Due to the drug interaction and interference of efficacies in a combined cancer therapy strategy, more unstable factors were involved in the process of clinical data analysis and this largely limits the case selection and efficacy evaluation for low PTX. To further reveal the efficacy of PTX in patients, there is a need for the accumulation of more cases and a broader range of long-term statistical surveys in future studies.
Taken together, our study indicates that avoiding long-term exposure to low-dose PTX, by optimization of the medication strategy and combining the PTX treatment with a regulator of liver drug metabolic enzymes, may be beneficial and feasible for the reasonable application of clinical breast cancer chemotherapy. 
Materials and methods
Primary tumor growth and metastasis detection in vivo
Specific pathogen free (SPF) nude mice were purchased from the Vital River Laboratory Animal Technology Co. Ltd (Beijing, China). MDA-231 cells (1 9 10 6 ) were subcutaneously transplanted. After the formation of primary tumors (diameter > 5 mm), the mice were randomly grouped (10 mice per group) and different doses of PTX were diluted with normal saline and administrated by intraperitoneal injection (1 time/2 days). After five cycles of treatment, the mice were euthanized. The primary tumor growth and metastatic intensities were then measured, and images were captured. The procedures of animal experiments mentioned in our study were approved by the Ani- 
Small-animal imaging assay
Metastatic 4T1 cells with stable firefly luciferase expression were provided by Caliper Life Sciences (Hopkinton, MA, USA). In this assay, 1 9 10 5 cells were resuspended in sterile PBS and subcutaneously injected into the inguinal area of 8-week-old female Balb/C mice. The tumor-bearing mice were randomly grouped (10 mice per group) after the formation of the primary tumor (about 10 days). Subsequently, the mice were intraperitoneally injected with PTX (1 time/2 days) to the end of the experiment. On the 40th day after drug administration, animals were sacrificed and the primary tumors, breast cancer preferential metastatic organs, including lungs, liver, brain and bones, were imaged and prepared for further analysis. All procedures were conducted in accordance with the China Experimental Animal Ethics Committee. The primary tumor growth and the pulmonary metastatic behaviors were dynamically visualized and quantified with the Image Station System (Kodak, Rochester, NY, USA). Before detection, 200 ll firefly D-luciferin potassium salt (reconstituted in sterile PBS to the concentration of 15 mgÁmL À1 ), which is the substrate for luciferase, was applied by hypodermic injection. After reaction for 10 min, the mice were anaesthetized by isoflurane and imaged.
Gene microarray analysis
For genome-wide gene expression analysis, MDA-231 cells were treated with 5 ngÁmL À1 PTX for 24 and 48 h and then cell lysates were prepared with TRIzol reagent. Then the total RNA in each group was extracted and the genome-wide gene expressing profile was obtained with the Human One Array (HOA) microarray system (Phalanx Biotech Group, Hsinchu, Taiwan). The expression information was statistically analyzed using the Rosetta Resolver databases and the targeted genes were screened by its P-value calculated by the t-test by comparing each probe's normalized intensities and the negative control probe's intensity. If the P-value was lower than the threshold (P < 0.05), it indicates the gene expression was significantly different compared with the negative control. The differential genes were further analyzed by cluster analysis.
Transwell cell migration assay
The cells were starved overnight and 1 9 10 5 cells were seeded into the upper chamber of a Transwell insert (8 lm pore size; BD Falcon, San Jose, CA, USA) containing serumfree medium. The medium (containing 10% FBS) was placed into the lower chambers. After culturing for 24 h, the cells on the top surface of the membrane were gently swabbed and the transmembrane cells were fixed with 4% paraformaldehyde and stained with crystal violet (0.1% in ethanol). The cell motility was further quantified by cell counting in five randomly selected fields by microscopy (9200).
RT-PCR analysis
The cell lysates (1 9 10 6 ) were prepared with TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA), and the total mRNA was extracted according to the manufacturer's instructions. Then, the total mRNA (1 lg) was digested with DNaseI at 37°C for 30 min and further reverse-transcribed using the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Burlington, ON, Canada). The protocol for cDNA synthesis was as follows: 45°C for 1 h followed by 70°C for 5 min. Then, the gene transcription intensity was detected by real-time PCR (ABI 7500 system, Thermo Fisher Scientific) by utilizing the primers described in Table S1 .
Cell detachment assay
Briefly, breast cancer cells (1 9 10 6 ) were treated with different concentrations of PTX and cultured for 24 h. Then, the cells were digested for a maximum of 40 min with 0.005% trypsin in Mg 2+ /Ca 2+ -free PBS. The trypsinized cells were imaged at the indicated time points. The cellular adhesion strength was assayed by determining the relative sensitivity to trypsin.
Statistical analysis
The results are expressed as the arithmetic mean AE standard deviation. All experiments were repeated at least three times and statistically analyzed by using IBM SPSS STATIS-TICS v. 19.0 (IBM, Armonk, NY, USA). One-way analysis of variance (one-way ANOVA) with least significant difference (LSD) or Tukey's post hoc test was used for all the quantifications (*P < 0.05; **P < 0.01, ***P < 0.001).
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